MarketCapExport financials
Marinus Pharmaceuticals (MRNS)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
Marinus Pharmaceuticals Financial Ratios 2023-2011 | MRNS
Brief overview of Marinus Pharmaceuticals's valuation multiples
This overview follows the five latest available observations from 2012 through 2023.
The valuation comparison uses P/S 16.03x (median 28.41x), P/B 29.62x (median 2.46x). The current ratio basket stands about 529.7% above the five-year base, increasing sensitivity to weak reports.
Returns on assets and capital are represented by ROE -8.4%, ROA -82.7%, ROCE -7.8%. Returns below zero mean resources are not producing positive profit. Recovery in operating results is the main reference point.
On PEG (1.64x), valuation is stretched relative to growth and requires strong execution.
A shorter cycle, from 174.8 days to 59.8 days, indicates faster release of cash from operations.
Valuation takeaway
Marinus Pharmaceuticals's market premium is not yet supported by strong capital returns, raising valuation risk.
Annual Financial Ratios Marinus Pharmaceuticals
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
P/E |
-3.5 | -14.4 | -4.4 | -4.9 | -2.2 | -46.4 | -162.2 | -2.8 | -18.3 | -24.0 | -23.6 | -46.4 | - |
P/S |
16.0 | 11.2 | 28.4 | 193.7 | - | - | - | - | - | - | - | 654.1 | - |
EPS |
-2.6 | -0.5 | -2.7 | -2.8 | -4.0 | -0.2 | -0.1 | -1.5 | -1.7 | -2.2 | -5.5 | - | - |
EV (Enterprise Value) |
530 M | 189 M | 396 M | 207 M | 37.9 M | 409 M | 738 M | 62.6 M | 417 M | 219 M | -7.67 M | 69.9 M | - |
EBITDA per Share |
-2.44 | -2.88 | -2.63 | -2.48 | -3.98 | -0.91 | -0.8 | -1.45 | -1.64 | -1.94 | -11.6 | -0.699 | - |
EV/EBITDA |
-4.0 | -1.7 | -4.1 | -3.1 | -0.7 | -11.0 | -39.0 | -2.2 | -17.1 | -18.4 | 1.4 | -40.3 | - |
PEG |
-0.06 | -0.22 | -0.08 | -0.1 | -0.04 | 1.64 | -0.58 | -0.07 | -0.15 | 0.03 | 0.4 | 1.73 | - |
P/B |
29.6 | 2.5 | 8.2 | 2.4 | 1.3 | 6.9 | 13.2 | 3.7 | 9.7 | 6.3 | 13.1 | 15.6 | - |
P/CF |
-4.2 | -2.5 | -7.9 | -5.5 | -2.4 | -16.9 | -40.8 | -3.2 | -22.7 | -7.9 | -18.7 | -53.0 | - |
ROE % |
-843.45 | -17.08 | -184.68 | -49.18 | -90.85 | -14.80 | -8.17 | -133.35 | -52.96 | -26.32 | 2.31 | -33.68 | - |
ROA % |
-82.74 | -7.64 | -72.18 | -44.85 | -54.76 | -13.44 | -7.81 | -91.08 | -41.66 | -21.57 | -11.79 | -16.22 | - |
ROCE % |
-784.28 | -97.23 | -181.23 | -48.62 | -86.92 | -54.41 | -32.76 | -120.88 | -46.78 | -24.74 | 8.91 | -34.11 | - |
Current Ratio |
1.1 | 1.8 | 1.6 | 11.3 | 8.9 | 10.9 | 22.8 | 3.2 | 4.7 | 5.5 | 5.0 | 1.9 | - |
DSO |
59.8 | 64.3 | 50.8 | 174.9 | - | - | - | - | - | - | - | - | - |
DPO |
- | - | 659.0 | - | - | - | - | - | - | - | - | - | - |
Operating Cycle |
59.8 | 64.3 | 50.8 | 174.8 | - | - | - | - | - | - | - | - | - |
Cash Conversion Cycle |
59.8 | 64.3 | -608.2 | 174.8 | - | - | - | - | - | - | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Quarterly Financial Ratios Marinus Pharmaceuticals
| 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
EPS |
-0.42 | -0.63 | -0.68 | - | -0.61 | -0.61 | -0.67 | - | 1.93 | -1.06 | -0.52 | - | -0.53 | -0.65 | -0.74 | - | -0.51 | -0.16 | -0.32 | -0.25 | -0.26 | -0.24 | -0.24 | -0.24 | -0.27 | -0.24 | -0.15 | -0.12 | -0.15 | -0.21 | -0.26 | -0.31 | -0.33 | -0.46 | -0.37 | -0.45 | -0.35 | -0.37 | -0.5 | -0.26 | -0.22 | -7.98 | -7.09 | -5.54 | -4.58 | -5.66 | -3.82 | - | - | - | - | - | - | - | - |
EBITDA per Share |
-0.36 | -0.56 | -0.63 | - | -0.58 | -0.59 | -0.63 | - | -0.8 | -0.98 | -0.45 | - | -0.51 | -0.64 | -0.74 | - | -0.51 | -0.16 | -0.22 | - | -0.26 | -0.24 | -0.24 | - | -0.28 | -0.24 | -0.15 | - | -0.15 | -0.2 | -0.26 | - | -0.33 | -0.45 | -0.36 | - | -0.34 | -0.36 | -0.49 | - | -0.26 | -5.88 | -5.71 | - | -2.67 | -3.53 | - | - | - | - | - | - | - | - | - |
ROE % |
286.81 | 194.82 | 78.33 | -156.97 | -67.60 | -828.15 | -820.37 | -779.55 | -804.40 | -918.84 | -121.36 | -73.45 | -91.36 | -82.00 | -100.25 | -76.72 | -102.59 | -125.20 | -136.37 | -114.67 | -103.61 | -94.72 | -89.16 | -78.84 | -72.20 | -47.29 | -54.12 | -71.08 | -90.91 | -108.41 | -108.15 | -97.68 | -85.90 | -81.02 | -70.99 | -73.38 | -65.93 | -50.36 | -27.67 | -12.92 | -1.85 | 3.95 | 1.69 | 2.31 | 2.03 | 2.79 | - | - | - | - | - | - | - | - | - |
ROA % |
-123.79 | -101.59 | -75.76 | -47.60 | -7.95 | -27.59 | -25.46 | -10.15 | -22.43 | -81.14 | -65.36 | -51.61 | -67.35 | -68.89 | -71.91 | -51.63 | -67.22 | -81.63 | -88.88 | -85.26 | -83.12 | -79.36 | -77.81 | -70.25 | -64.62 | -44.68 | -45.76 | -55.13 | -66.45 | -76.73 | -75.51 | -68.91 | -62.54 | -59.31 | -52.78 | -54.22 | -48.65 | -38.66 | -60.86 | -50.19 | -54.80 | -61.64 | -40.82 | -11.79 | -10.35 | -14.23 | - | - | - | - | - | - | - | - | - |
ROCE % |
259.61 | 173.20 | 66.37 | -151.60 | -188.30 | -895.76 | -882.28 | -843.54 | -867.96 | -855.97 | -114.04 | -72.68 | -90.63 | -81.92 | -100.94 | -77.39 | -118.19 | -127.09 | -133.10 | -89.37 | -121.32 | -101.78 | -86.43 | -64.71 | -71.50 | -67.23 | -73.94 | -62.44 | -86.30 | -106.87 | -96.69 | -68.71 | -87.61 | -81.05 | -73.61 | -56.11 | -61.62 | -37.77 | -26.94 | -7.03 | -4.84 | 3.39 | -6.48 | - | 2.19 | 2.72 | - | - | - | - | - | - | - | - | - |
Current Ratio |
0.5 | 0.7 | 0.9 | 1.1 | 1.4 | 1.4 | 1.6 | 1.8 | 1.8 | 1.1 | 1.4 | 1.6 | 2.0 | 4.2 | 7.2 | 11.3 | 8.2 | 9.2 | 6.4 | 8.9 | 3.9 | 4.8 | 6.8 | 10.9 | 6.0 | 13.3 | 28.8 | 22.8 | 25.3 | 3.8 | 3.5 | 3.1 | 3.2 | 3.3 | 4.3 | 4.7 | 3.3 | 3.7 | 4.0 | 5.5 | 14.3 | 1.9 | 5.5 | 5.0 | 5.0 | 5.0 | - | - | - | - | - | - | - | - | - |
DSO |
38.9 | 39.4 | 43.4 | - | 59.2 | 127.0 | 79.3 | - | 124.8 | 139.9 | 16.5 | - | 11.2 | - | 41.6 | - | 439.2 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
DPO |
- | - | - | - | - | - | - | - | - | 311.1 | 304.3 | - | 123.6 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Cycle |
38.9 | 39.4 | 43.4 | - | 59.2 | 127.0 | 79.3 | - | 124.8 | 139.9 | 16.5 | - | 11.2 | - | 41.6 | - | 439.2 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cash Conversion Cycle |
38.9 | 39.4 | 43.4 | - | 59.2 | 127.0 | 79.3 | - | 124.8 | -171.2 | -287.9 | - | -112.4 | - | 41.6 | - | 439.2 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
Multiples are an important financial analysis tool for the company Marinus Pharmaceuticals, allowing investors and analysts to quickly assess the company’s value and investment attractiveness based on the ratio of market indicators to the company’s financial performance. Essentially, multiples express how the market values the company relative to its earnings, revenue, equity, or other key metrics.
Advantages of Using Financial Ratios- Simplified Data Analysis
Financial ratios transform large volumes of accounting data into compact and easily interpretable indicators, significantly simplifying the assessment of the company’s condition. - Comparability Between Companies
Multiples standardize financial metrics, enabling objective comparison of companies of different sizes, industries, and market capitalizations. - Identification of Trends and Issues
Regular analysis of ratios helps track the dynamics of financial health, identify strengths and weaknesses of the business, as well as potential risks. - Decision Support
Financial multiples serve as an important tool for investors, creditors, and company management in making investment, credit, and managerial decisions. - Accelerated Assessment of Investment Attractiveness
Ratios allow quick determination of key performance, liquidity, and financial stability indicators, facilitating prompt evaluation of companies’ attractiveness for investments.
Using multiples enables comparison between companies, even if they differ in size or industry, as they standardize financial data into ratios convenient for analysis. This is especially useful for evaluating companies where direct analysis of financial statements may be complex or require in-depth knowledge.
Britain
USA
China
Germany
Schweiz
France
Australia
Israel
